Genomma Lab Internacional, S.A.B. de C.V.
GNMLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$729.14M
Close$
$1.74
140.4% upside
Current Fair Value
140.4% upsideUndervalued by 140.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $729.14 Million |
|---|---|
| Enterprise Value | $6.43 Billion |
| Annual dividend | $0.04 |
| Dividend yield | 5.24% |
| Earnings per Share | $1.65 |
| Beta | 0.14 |
| Outstanding Shares | 1,009,608,000 |
Return
| Return on Equity | 14.47% |
|---|---|
| Return on Assets | 7.04% |
| Return on Invested Capital | 28.23% |
Valuation & Multiples
| P/E Ratio | 8.87 |
|---|---|
| PEG | 47.64 |
| Price to Sales | 0.05 |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | 0.38 |
| Enterprise Value to EBIT | 1.54 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 1.26 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 21, 2026
EPS Estimate
$0.02
Consensus analyst estimateRevenue Estimate
$241.75 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
$0.02
Consensus analyst estimateRevenue Estimate
$235.92 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Genomma Lab Internacional, S.A.B. de C.V.
1,465 employees
CEO: Juan Marco Sparvieri
Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items. Its operat...